Alto Neuroscience Inc. (ANRO)
| Bid | 2.16 |
| Market Cap | 61.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.43M |
| EPS (ttm) | -2.5 |
| PE Ratio (ttm) | -0.9 |
| Forward PE | -0.75 |
| Analyst | Buy |
| Ask | 2.28 |
| Volume | 135,785 |
| Avg. Volume (20D) | 329,695 |
| Open | 2.19 |
| Previous Close | 2.25 |
| Day's Range | 2.15 - 2.27 |
| 52-Week Range | 1.60 - 17.55 |
| Beta | 2.16 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphod...
Analyst Forecast
According to 6 analyst ratings, the average rating for ANRO stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 342.48% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Alto Neuroscience to Participate in Upcoming Investor ConferencesMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel pre...
